TABLE II:

Baseline Demographics and Clinical Characteristics of Carnitine and Placebo-treated Male Septic Shock Patients

Variable	Carnitine-treated (n=11)	Placebo-treated (n=10)	p value
Age (IQR)	62 (51–74)	66.5 (55–70)	0.54
Race, n (%)
African American	2 (18)	2 (20)	>0.99
Caucasian	9 (82)	8 (80)	>0.99
Comorbidities, n (%)
Coronary artery disease	4 (36)	2 (20)	0.64
Cerebrovascular accident	1 (30)	2 (20)	0.59
Hypertension	7 (64)	7 (70)	>0.99
Type I DM	1 (9)	4 (40)	0.15
Type II DM	2 (18)	1 (10)	>0.99
Chronic renal insufficiency	3 (27)	2 (20)	>0.99
Malignancy	1 (9)	3 (30)	0.31
T0 Total SOFA score (IQR)	14 (9–14)	8 (6–12)	0.02

IQR, interquartile range; DM, diabetes mellitus; SOFA, Sequential Organ Failure Assessment score; age and SOFA values are median.